Key insider moves
Liquidia Corp (NASDAQ:LQDA) Chief Commercial Officer Scott Moomaw completed two stock sale transactions on March 23, 2026, disposing of a combined 18,314 shares of the company’s common stock. The dispositions were executed pursuant to a pre-arranged 10b5-1 trading plan and comprised two tranches. The first tranche consisted of 1,314 shares sold at $36.48 per share for proceeds of $47,934. The second tranche involved 17,000 shares sold at prices ranging from $36.13 to $37.20, yielding an average sale price of $36.8128 and total proceeds of $625,817.
Option exercise and resulting ownership
On the same date, Moomaw exercised incentive stock options to acquire 17,000 shares of Liquidia common stock at an exercise price of $3.40 per share for a total exercise cost of $57,800. After these transactions, Moomaw’s direct holdings in Liquidia amount to 187,640 shares, a total that encompasses unvested restricted stock units (RSUs) and shares purchased via the company’s employee stock purchase plan.
Market context and valuation signals
The insider activity took place against a backdrop of notable price performance for Liquidia. The shares have returned 126% over the past year and were trading at $36.60 at the time of the report, representing a market capitalization of $3.21 billion. InvestingPro notes that, based on Fair Value analysis, the stock appears undervalued and reports that analysts project Liquidia will become profitable this year. InvestingPro also provides 13 additional ProTips for LQDA and offers comprehensive Pro Research Reports covering LQDA and more than 1,400 other U.S. equities.
Recent operating and commercial developments
Liquidia reported fourth-quarter 2025 results that reflected a strong revenue performance alongside an earnings-per-share shortfall. Revenue attributable to the company’s Yutrepia drug totaled $90.1 million for the quarter, representing a 74% increase from the prior quarter. Management has also issued revenue guidance that exceeds $1 billion for 2027.
Analyst reactions
Several brokerages have adjusted their price targets upward following the quarter and the Yutrepia launch. H.C. Wainwright raised its price target on Liquidia to $55, while BTIG lifted its target to $50. Raymond James reiterated a Strong Buy rating with a $47 price target, stating that Yutrepia’s early launch results are comparable to those of Tyvaso DPI. BofA Securities maintained a Buy rating and a $44 price target, citing Liquidia’s competitive position in the prostacyclin treatment area.
What this means
The transactions by Moomaw combined a structured sale under a 10b5-1 plan with the exercise of incentive options at a substantially lower strike price, resulting in both liquidity realization and increased direct share ownership. The sales and option exercise occurred while the stock has shown substantial year-over-year appreciation, and amid analyst commentary and price-target revisions tied to Yutrepia’s rollout and recent quarterly revenue performance.
Limitations and notes
The information presented here reports transaction details, company results, analyst commentary, and third-party valuation observations as stated. Where analysis or projections are referenced, they reflect the statements attributed to analysts or the InvestingPro service and are not new forecasts introduced in this report.